About
Cognito Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for Alzheimer's disease. Their lead product candidate, Spectris™, is a non-invasive, wearable neurostimulation device designed to treat cognitive decline associated with Alzheimer's. The company aims to address the underlying pathology of the disease by modulating brain activity.
Tags
Performance
Company Timeline
No timeline data for this period
Score Breakdown
58Traction
40Team
60Visibility
8Profile
0Community
15Discussion (0)
Join the discussion
No comments yet. Be the first to share your thoughts!
Frequently Asked Questions
What does Cognito Therapeutics do?
Cognito Therapeutics is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic approach for Alzheimer's disease. Their lead product candidate, Spectris™, is a non-invasive, wearable neurostimulation device designed to treat cognitive decline associated with Alzheimer's. The company aims to address the underlying pathology of the disease by modulating brain activity.
How much funding has Cognito Therapeutics raised?
Cognito Therapeutics has raised a total of $213M in funding. The most recent round on record is Series C.
Where is Cognito Therapeutics headquartered?
Cognito Therapeutics is headquartered in Boston, Massachusetts, USA.
When was Cognito Therapeutics founded?
Cognito Therapeutics was founded in 2011.
What industry does Cognito Therapeutics operate in?
Cognito Therapeutics operates in Biotechnology, Medical Devices, Neuroscience, Healthcare.
Similar Startups